ARVEN Trademark

Trademark Overview


On Wednesday, October 1, 2014, a trademark application was filed for ARVEN with the United States Patent and Trademark Office. The USPTO has given the ARVEN trademark a serial number of 79164550. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, May 5, 2023. This trademark is owned by ARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI. The ARVEN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals;...
arven

General Information


Serial Number79164550
Word MarkARVEN
Filing DateWednesday, October 1, 2014
Status709 - CANCELLED - SECTION 71
Status DateFriday, May 5, 2023
Registration Number5061369
Registration DateTuesday, October 18, 2016
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 2, 2016

Trademark Statements


Goods and ServicesPharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; Pharmaceuticals and pharmaceutical preparations, namely, dry powder inhalers filled with pharmaceutical preparations for the treatment of asthma and respiratory diseases; Inhalation products, namely, inhalers filled with pharmaceutical preparations for the treatment of asthma, respiratory diseases; pharmaceutical preparations used in medical diagnostic procedures, namely, contrast media for use with x-ray, magnetic resonance and ultrasound equipment; veterinary preparations for medical use, namely, anesthetics, combination sedative, analgesic; veterinary preparations for medical use for the treatment of bacterial infections; pharmaceutical preparations, namely, Systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; mineral preparations, namely, vitamin and mineral supplements, vitamin and mineral preparations for medical use, vitamin preparations and mineral supplements; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and cardiovascular treatment preparations and cardiovascular agents for medical purposes; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, antiparkinson preparations; Pharmaceuticals for the treatment of respiratory diseases and asthma; Dermatological pharmaceutical products; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use; pharmaceutical preparations for the treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, erectile dysfunction, respiratory diseases, allergy, ophthalmic diseases, containing one or more of the following active ingredients - cromolin sodium, amlodipin besylate, alendronate sodium, chlorazepate dipotassium, atropine sulphate, atorvastatin calcium, candesartan cilexetil, ceftriaxone sodium, ephedrine hcl, guaiphenesine, zafirlukast, donepezil hcl, diflunisal, dipyridamole, famotidine, losartan potassium, hydro-chlorothiazide, meloxicam, phenyleprine hcl, fexofenadine hcl, indapamide, sulfisoxazole, clopidogrel, lansoprazole, clarithromycin, flurbiprofen, nimesulide, pantoprazole, paracetamole, pilocarpine hcl, lisinopril, pseudoephedrine hcl, ciprofloxacin hcl, sertraline hcl, cyclopentolate hcl, dihydroergotoxine methansulfonate, terbinafine, timolol maleate, tiamphenicol, azithromycin, tenoxicam, fluconazole, digoxine, tioconazole, dimenhydrinate, quinidine arabogalactane sulphate, quinidine phenylethyl barbiturate, diltiazem hcl, buspirone hcl, amiodarone hcl, trazodone, difluprednate, enoxacin, lactulose, ketorolac, pentoxifylline, vitamin e, chlorhexidine, cetrimide, propyphenazone, caffeine, cetirizine, phenylpropanolamine, zolpidem, bacampicillin hcl, roxithromycin, sultamicillin tosilate, acetylsalicylic acid, ampicillin na, sulbactam na, sildenafil citrate, ambroxol hcl, ribavirin, loratadine, etodolac, omeprazole, oxybutynin chloride, quinidine sulphate, olanzapine, raloxifen, pioglitazone, moxifloxacin, rosiglitazone, sibutramin, carvedilol, montelukast, citalopram, gliclazide, cefaclor, ezetimibe, rofecoxib, quetiapine fumarate, metformin hcl, acarbose, chlorpheniramine maleate, nateglinide, leflunomide, valsartan, cefazolin sodium, diacerein, paroxetine, levofloxacin, levetiracetam, zolmitriptan, glibenclamide, tizanidine, perindopril erbumine, ramipril, ceftazidime, cefuroxime axetyl, thiocolchicoside, acamprosate, acetylcysteine, alpha calcidol, alpha lipoic acid, aripiprazole, atomoxetine, balsalazide disodium, butenafine hcl, calcitriol, carbonyl iron, folic acid, calcium carbonate, magnesium hydroxide, cefdinir, cefepime hcl, cefixime, cefpodoxime proxetil, cefprozil, cephalexine monohydrate, ciclesonide, cilazapril, cilostazol, cinitapride, citicoline, co-enzyme q10, darifenasin, deferiprone, dothiepin, duloxetine, eletriptan, escitalopram, esomeprazole, etoricoxib, felodipine, fenofibrate, ferrous sulphate, zinc sulphate, fluvastatin, frovatriptan, gabapentin, galantamine, gemifloxacin, ginkgo biloba, glimepride, granisetron, ibandronate, irbesartan, iron hydroxide polymaltose, lamivudine, lamotrigine, levetiracetam, letrozole, linezolide, memantine hcl, metoprolol, midodrine, mirtazapine, mizolastine, mosapride citrate dihydrate, mycophenolate mofetil, nebivolol, nefazodone, niacin, nitazoxanide, ondansetron, ornidazole, oxcarbazepine, pimecrolimus, pravastatin, pregabalin, rabeprazol, rebamipide, repaglinide, risedronate, risperidone, rivastigmine, rosuvastatin, saccharomyces boulardii, tacrolimus, tadalafil, tamsulosin hcl, tazaroten, tazobactam sodium, piperacillin sodium, tegaserod, telithromycin, terazocin, teriparatide, tolterodine tartrate, topiramate, trandolapril, trimethazidine, valacyclovir, valproate sodium, venlafaxine, voriconazole, ximelagatran, zaleplon, ziprasidone, zoledronic acid
Translation of Words in MarkThe wording "ARVEN" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, May 5, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Party Type30 - Original Registrant
Legal Entity Type09 - Joint Stock Company
AddressTR-34460 ISTANBUL
TR

Party NameARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Party Type20 - Owner at Publication
Legal Entity Type09 - Joint Stock Company
AddressTR-34460 ISTANBUL
TR

Party NameARVEN ILAÇ SANAYI VE TICARET ANONIM SIRKETI
Party Type10 - Original Applicant
Legal Entity Type09 - Joint Stock Company
AddressIstinye-Sari
TR

Trademark Events


Event DateEvent Description
Monday, February 5, 2024TOTAL INVALIDATION PROCESSED BY THE IB
Wednesday, January 17, 2024GENERIC MADRID TRANSACTION SENT TO IB
Wednesday, January 17, 2024GENERIC MADRID TRANSACTION CREATED
Friday, January 5, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, May 5, 2023CANCELLED SECTION 71
Monday, October 18, 2021COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, May 7, 2020NEW REPRESENTATIVE AT IB RECEIVED
Thursday, January 25, 2018NEW REPRESENTATIVE AT IB RECEIVED
Friday, July 14, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, February 23, 2017GENERIC MADRID TRANSACTION SENT TO IB
Thursday, February 23, 2017GENERIC MADRID TRANSACTION CREATED
Wednesday, January 18, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, November 18, 2016NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, October 18, 2016REGISTERED-PRINCIPAL REGISTER
Wednesday, October 12, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 12, 2016NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Friday, August 12, 2016NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, August 2, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 2, 2016PUBLISHED FOR OPPOSITION
Wednesday, July 13, 2016NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, July 13, 2016NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, July 13, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 29, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, June 23, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 23, 2016EXAMINER'S AMENDMENT ENTERED
Thursday, June 23, 2016NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 23, 2016EXAMINERS AMENDMENT E-MAILED
Thursday, June 23, 2016EXAMINERS AMENDMENT -WRITTEN
Tuesday, January 5, 2016NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 5, 2016FINAL REFUSAL E-MAILED
Tuesday, January 5, 2016FINAL REFUSAL WRITTEN
Tuesday, December 15, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 15, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 10, 2015ASSIGNED TO LIE
Monday, November 30, 2015ASSIGNED TO LIE
Thursday, November 12, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 2, 2015REFUSAL PROCESSED BY IB
Monday, June 1, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, June 1, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 15, 2015APPLICATION FILING RECEIPT MAILED
Wednesday, May 13, 2015NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, May 13, 2015REFUSAL PROCESSED BY MPU
Wednesday, May 13, 2015NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, May 12, 2015NON-FINAL ACTION WRITTEN
Monday, May 11, 2015ASSIGNED TO EXAMINER
Monday, May 11, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 7, 2015SN ASSIGNED FOR SECT 66A APPL FROM IB